Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial...

Area of Science:

• Cardiovascular Medicine
• Inflammation Research
• Biomarker Discovery

Background:

• Inflammation is implicated in atherosclerosis development.
• Inflammatory markers are explored for cardiovascular risk prediction, but data are limited.
• Interleukin-6 (IL-6), soluble CD40 ligand (sCD40L), metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) are key inflammatory markers.

Purpose of the Study:

• To assess serum levels of IL-6, sCD40L, MMP-9, and TIMP-1 in acute ST-segment elevation myocardial infarction (STEMI) patients.
• To evaluate the prognostic ability of these inflammatory markers for cardiovascular mortality.
• To determine if IL-6 is an independent predictor of cardiovascular mortality in STEMI patients.

Main Methods:

• Prospective cohort study of 263 first STEMI patients admitted within 6 hours of symptom onset.
• Serum levels of IL-6, sCD40L, MMP-9, and TIMP-1 measured via sandwich ELISA at admission.
• 3-year prospective follow-up for cardiovascular mortality, with data available for 228 patients.

Main Results:

• Kaplan-Meier analysis showed significantly increased cardiovascular mortality with higher IL-6 levels (P = 0.0002).
• Logistic regression identified IL-6 as an independent predictor of cardiovascular mortality.
• No significant prognostic value reported for sCD40L, MMP-9, or TIMP-1 in this cohort.

Conclusions:

• Elevated admission IL-6 levels in STEMI patients are valuable for long-term cardiovascular risk stratification.
• IL-6 emerges as a significant independent predictor of mortality post-STEMI.
• Further research may validate IL-6 as a routine clinical biomarker for STEMI prognosis.